Presenting new epidemiological and diabetes-related impact data.
The International Diabetes Federation (IDF) has presented the interim results of the first-ever multi-country online survey on CVD risk awareness and knowledge among people living with type 2 diabetes, indicating low levels of awareness and limited dialogue between patients and healthcare professionals.
The global survey – Taking Diabetes to Heart – developed in partnership with Novo Nordisk, runs until March 2018 and is open to all people with type 2 diabetes. The interim results were presented at the IDF Congress 2017 in Abu Dhabi, UAE.
Diabetes currently affects 425 million adults worldwide1, with most cases being type 2 diabetes. Cardiovascular disease, which includes stroke, coronary heart disease and peripheral artery disease3, is the leading cause of disability and death in people with type 2 diabetes1,4.
To date, 943 responses to the survey have been received from 32 countries and interim findings show that:
“The interim results of Taking Diabetes to Heart reiterate the importance of raising awareness of the association between type 2 diabetes and cardiovascular disease to promote prevention, timely diagnosis and appropriate treatment to help reduce the current burden that the two conditions represent,” said Dr. Shaukat Sadikot, outgoing IDF President. “With the world facing an increase in the prevalence of type 2 diabetes1, better understanding the link between these conditions is needed more than ever.”
Taking Diabetes to Heart – www.idf.org/takingdiabetes2heart/survey – aims to gather insights on current gaps in education and CVD risk behaviour among people with type 2 diabetes, and to put in place advocacy and patient support strategies and tactics to improve health and wellbeing among populations.
”Cardiovascular disease is the leading cause of disability and death among people living with type 2 diabetes. Too few individuals with diabetes are being informed by healthcare professionals of their cardiovascular risk and the impact that risk may have on their longevity and quality of life,” said Alan Moses, senior vice president and chief medical officer of Novo Nordisk. “We encourage more people in the diabetes community to complete the Taking Diabetes to Heart survey to strengthen the global findings that will inform future efforts to help improve outcomes.”
The results of Taking Diabetes to Heart will serve to define the actions that are required to improve the health outcomes of people with type 2 diabetes. The initiative will culminate in a comprehensive report with country specific results and resources to help support knowledge and awareness of CVD among people with type 2 diabetes around the world.